BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 23033268)

  • 21. A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count.
    Tefferi A; Loscocco GG; Farrukh F; Szuber N; Mannelli F; Pardanani A; Hanson CA; Ketterling RP; De Stefano V; Carobbio A; Barbui T; Guglielmelli P; Gangat N; Vannucchi AM
    Am J Hematol; 2023 Dec; 98(12):1829-1837. PubMed ID: 37665758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.
    Alvarez-Larrán A; Cuevas B; Velez P; Noya S; Caballero-Navarro G; Ferrer-Marín F; Carbonell S; Pérez-Encinas M; Gómez-Casares MT; Pérez-López R; Magro E; Moretó A; Pastor-Galán I; Angona A; Mata-Vázquez MI; Guerrero-Fernández L; Guerra JM; Carreño-Tarragona G; Fox L; Murillo I; García-Gutiérrez V; Mora E; Stuckey R; Arellano-Rodrigo E; Hernández-Boluda JC; Pereira A
    Hemasphere; 2023 Aug; 7(8):e936. PubMed ID: 37476303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia.
    Mudireddy M; Barraco D; Hanson CA; Pardanani A; Gangat N; Tefferi A
    Am J Hematol; 2017 May; 92(5):454-459. PubMed ID: 28211153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history.
    Gangat N; Wassie EA; Lasho TL; Finke C; Ketterling RP; Hanson CA; Pardanani A; Wolanskyj AP; Maffioli M; Casalone R; Passamonti F; Tefferi A
    Eur J Haematol; 2015 Jan; 94(1):31-6. PubMed ID: 24889737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.
    Barbui T; Vannucchi AM; Buxhofer-Ausch V; De Stefano V; Betti S; Rambaldi A; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Gisslinger H; Finazzi G; Carobbio A; Thiele J; Passamonti F; Falcone C; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e369. PubMed ID: 26617062
    [No Abstract]   [Full Text] [Related]  

  • 26. Developments in diagnosis and treatment of essential thrombocythemia.
    Mora B; Passamonti F
    Expert Rev Hematol; 2019 Mar; 12(3):159-171. PubMed ID: 30793984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of major bleeding events in 1381 patients with essential thrombocythemia.
    Stuckey R; Ianotto JC; Santoro M; Czyż A; Encinas MMP; Gómez-Casares MT; Pereira MSN; de Nałęcz AK; Gołos A; Lewandowski K; Szukalski Ł; González-Martín JM; Sobas MA
    Int J Hematol; 2023 Nov; 118(5):589-595. PubMed ID: 37660316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases.
    Gangat N; Jadoon Y; Szuber N; Hanson CA; Wolanskyj-Spinner AP; Ketterling RP; Pardanani A; Tefferi A
    Blood Cancer J; 2022 Mar; 12(3):44. PubMed ID: 35301278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DETERMINING THE RISK OF THROMBOSIS AMONG THE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA.
    Ghirdaladze D; Vatsadze T; Kirtava T
    Georgian Med News; 2020 Feb; (299):143-146. PubMed ID: 32242862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What factors determine the pregnancy outcome in patients with essential thrombocythemia?
    Kwiatkowski J; Kuliszkiewicz-Janus M; Potoczek S; Jaźwiec B; Wróbel T; Małecki R
    J Matern Fetal Neonatal Med; 2022 Dec; 35(24):4734-4738. PubMed ID: 33792458
    [No Abstract]   [Full Text] [Related]  

  • 31. [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
    Pósfai É; Marton I; Nemes A; Borbényi Z
    Orv Hetil; 2015 Apr; 156(14):558-63. PubMed ID: 25819149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukocytosis and risk stratification assessment in essential thrombocythemia.
    Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
    J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. It is time to change thrombosis risk assessment for PV and ET?
    Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
    Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
    Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of clonality assessment in JAK2V617F-negative essential thrombocythemia.
    Martínez-Avilés L; Álvarez-Larrán A; Besses C; Navarro G; Torres E; Longarón R; Angona A; Pedro C; Florensa L; Serrano S; Bellosillo B
    Ann Hematol; 2012 Oct; 91(10):1555-62. PubMed ID: 22706669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria.
    Finazzi G; Carobbio A; Thiele J; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Randi ML; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Gangat N; Rambaldi A; Tefferi A; Barbui T
    Leukemia; 2012 Apr; 26(4):716-9. PubMed ID: 21926959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinico-hematological profile and thrombotic/hemorrhagic events in 150 chinese patients with essential thrombocythemia.
    Zhou D; Chen W; Cheng H; Qiao JL; Zhu LL; Li ZY; Xu KL
    Leuk Res; 2018 Jun; 69():1-6. PubMed ID: 29609040
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia.
    Chen J; Dong H; Fu R; Liu X; Xue F; Liu W; Chen Y; Sun T; Ju M; Dai X; Li H; Wang W; Chi Y; Yang R; Zhang L
    J Thromb Thrombolysis; 2023 Aug; 56(2):291-300. PubMed ID: 37249742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.